Menu
ncarol.com
  • Home
  • Music
  • Books
  • Manufacturing
  • Asheville Music
  • Health
  • Book Release
  • Business
  • Technology
ncarol.com

Lineus Medical's CEO Vance Clement joins the 2025 Association of Vascular Access Board of Directors
ncarol.com/10269488

Trending...
  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
  • Heritage at Manalapan Welcomes New Sales Team as Luxury Single-Family Home Community Continues to Grow
Lineus Medical CEO, Vance Clement AVA Logo Lineus Medical
FAYETTEVILLE, Ark. - ncarol.com -- Vance Clement, CEO of Lineus Medical, has been selected to join the Association of Vascular Access (AVA) Board of Directors as a Director at Large for a two-year term. AVA is an association of healthcare professionals whose mission is to advance the global practice of vascular access, through awareness, advocacy, and education to improve healthcare outcomes. Since 1985, they have worked to improve vascular access care and promote vascular access specialty. During Vance's time on the board, he will highlight the importance of vascular access care, provide support to local vascular access networks (VAN) across the nation, and grow AVA's membership.  When asked about being selected to join the board Vance said, "It is an honor to join the AVA Board of Directors.  I consider AVA to be the preeminent organization for anyone working in the vascular access space.  I look forward to helping AVA grow its membership."

Vance Clement has worked in the medical device industry for over 30 years. He is a frequent speaker at VAN chapter meetings across the country. He has served as the co-founder and CEO of Lineus Medical since 2015 and is passionate about improving IV care and advancing the science around IV care. Under his leadership, Lineus Medical brought the first break away device for medical lines, SafeBreak Vascular, to market.

More on ncarol.com
  • Bettingbladet releases H1 2026 report on the Swedish online gambling market
  • Garage door installation or repair in Minnesota? Which makes more sense for your family?
  • Super Rooter Expands to 190 Plumbing, Sewer, and Drain Service Locations Across the United States
  • Google AI Says KayeDinero Isn't the Greatest Female Producer. She Asks: Who Decides?
  • European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP

SafeBreak Vascular is the only break-away device for IV lines proven to reduce IV complications.1 When a harmful force is placed on the line, SafeBreak intentionally separates to remove the damaging force and protect the patient's IV. When SafeBreak separates, valves on both ends of the device close preventing medicine spills from the pump and blood loss from the patient. To replace SafeBreak, each component is unthreaded from the line, a new sterile SafeBreak is installed, and the patent's infusion is restarted. Patients avoid additional needlesticks, nurses save time, and hospitals save money1.

About Lineus Medical

Lineus Medical is the developer of a break-away technology that is proven to reduce IV restarts and IV complications1. Our mission is to remove the pains associated with medical lines. More information about Lineus Medical can be found at www.lineusmed.com. Follow Lineus Medical on LinkedIn.

1.          Data on File

MKG 0287 Rev 00

Contact
Vance Clement
***@lineusmed.com


Source: Lineus Medical
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Cress Creeks Farm Opens Fall Corn Maze and Baby Lamb Hayride Experience in Ellijay, Georgia
  • Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
  • Pipeline Developer Isn't Just a Song: KayeDinero Builds Software, Markets and Music
  • Who Is KayeDinero? The Asheville Artist Also Builds Software and Trading Systems
  • Leaping Cat Creative Takes Shape Around the Problems Nobody Quite Owns
  • White Coat Financial Partners Announces Launch of Next Generation Practice Optimization Software
  • Kerri Lawless Introduces New Home-Selling Option for Local Homeowners
  • As Boone Takes Art to the Streets, KayeDinero Asks What Makes Creativity Human
  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
  • Black Mountain Meets "Human Error": KayeDinero on What Technology Can't Reproduce
  • As Brevard Heads Into Mountain Song Weekend, KayeDinero Brings a Different Kind of WNC Sound
  • Why Did KayeDinero Put Haywood Road Into a Song?
  • Shelter Structures America makes European debut at TEMPOR EXPO 2026 in Fulda, Germany
  • TekTone innovation meets patient care
  • HydroExcavation.com Relaunches With Exclusive Local Service Areas and Dedicated Hydrovac Manufacturer Directory
  • Sky Quarry Enters a Powerful New Chapter: Refinery Restart Emminent, Nevada Oil Initiative and Visibility Put (NAS DAQ: SKYQ) in the Spotlight
  • OneVizion Launches Vera AI, Bringing Connected Operational Context to Infrastructure Teams
  • P-Wave Press Announces Pushing the Wave 2025 by L.A. Davenport
  • DONGSHENG Titanium Recycling: Promoting a Closed-Loop Cycle for High-End Titanium Materials
_catLbl0 _catLbl1

Popular on ncarol.com

  • Mito Health Passes One Million Lab Tests, Expands to Seven Categories of Preventive Health Testing - 156
  • Parksy (parksy.com) Tackles the Most Common Parking Problem Nobody Talks About: Finding the Car Again - 155
  • Free JavaScript Charting Library ProEssentialsJS Permits Commercial Use. Highcharts, SciChart and LightningChart Free Tiers Do Not - 139
  • 5X Gross Margin Improvement to Beat EPS Consensus; $54.6 Million 10-Year Contract Award Puts Cybersecurity Leader on Path to a $30 Million Run Rate - 133
  • Robert DeMaio, Phinge CEO to Speak at 30th IIPLA 2026 on Securing IP, User Data & Digital Sovereignty via Verified App-less Tech. Attend the Live Q&A! - 123
  • Bspin Launches Lightning-Fast Crypto Gaming Expansion With Sportsbook, Poker, VIP Rewards, and Bitcoin Lightning Network Integration - 122
  • BumbleBeeSmart Launches Dedicated Sensory Wall Panels Collection for Adults, Memory Care and Senior Living - 122
  • From Temecula Wine Country to Canyon Lake: Parkway Construction Transforms Outdoor Spaces for Inland Homeowners - 121
  • Project CIVICA Report Finds 10,680 Non-Citizen Indicators on New York Voter Rolls — Including 88 Records with Recent Voting History - 119
  • Patented Foodservice Products Company with Strong Gross Margins and Substantial Two-Year Revenue Growth Hits Market for $1.6 Million - 112

Similar on ncarol.com

  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Houston This October
  • Lawsuit Alleges American Deli Food Caused Severe Illness, Acute Kidney Failure, And Eight-day Hospitalization
  • Google AI Says KayeDinero Isn't the Greatest Female Producer. She Asks: Who Decides?
  • European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP
  • "Kulture Metrics" Isn't Just an Album Title: KayeDinero Connects Music, Markets and Code
  • Congressman Chuck Edwards (NC-11) Presents ReadyCommunities Partnership 2026 National Service Award to Local Businessman / US Air Force Veteran
  • Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
  • Pipeline Developer Isn't Just a Song: KayeDinero Builds Software, Markets and Music
  • White Coat Financial Partners Announces Launch of Next Generation Practice Optimization Software
  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute